Free tool
FAERS Monitor: Suprax
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203195 or its brand name (Suprax, Cefixime). Reports on generic versions are filed under their own applications.
Reports
3,061
Serious
2,619
86% of reports
Hospitalization
1,427
Death reported
212
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use299
- drug ineffective292
- pyrexia175
- diarrhoea174
- nausea173
- pain158
- malaise141
- fatigue138
- headache136
- vomiting136
- dyspnoea134
- abdominal pain117
- condition aggravated117
- asthenia93
- constipation92
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 5 |
| 2006 | 2 |
| 2007 | 8 |
| 2008 | 1 |
| 2009 | 9 |
| 2010 | 20 |
| 2011 | 41 |
| 2012 | 43 |
| 2013 | 44 |
| 2014 | 46 |
| 2015 | 55 |
| 2016 | 102 |
| 2017 | 64 |
| 2018 | 137 |
| 2019 | 227 |
| 2020 | 254 |
| 2021 | 281 |
| 2022 | 409 |
| 2023 | 409 |
| 2024 | 328 |
| 2025 | 351 |
| 2026 | 215 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,098 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pyrexiaSignal | 175 | 3.5 | 3.0 | 311 |
| abdominal painSignal | 117 | 3.5 | 2.9 | 204 |
| constipationSignal | 92 | 2.9 | 2.4 | 114 |
| condition aggravatedSignal | 117 | 2.6 | 2.2 | 120 |
| off label useSignal | 299 | 2.3 | 2.1 | 240 |
| malaiseSignal | 141 | 2.2 | 1.9 | 94 |
| vomiting | 136 | 2.0 | 1.7 | 67 |
| diarrhoea | 174 | 1.9 | 1.6 | 70 |
| pain | 158 | 1.8 | 1.5 | 53 |
| asthenia | 93 | 1.7 | 1.4 | 27 |
| dyspnoea | 134 | 1.6 | 1.4 | 33 |
| drug ineffective | 292 | 1.5 | 1.4 | 55 |
| nausea | 173 | 1.5 | 1.3 | 30 |
| headache | 136 | 1.5 | 1.3 | 22 |
| fatigue | 138 | 1.2 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.